RxDoctor Payments Data

Steven Maislos, MD

Urology · Houston, TXNPI 1760418503

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $123,226 of the $157,680 with a category attached, or 78.1%. It is spread thinly across 39 manufacturers, the largest accounting for just 19.0%. Reporting peaked in 2019 at $47,836 and has fallen 68.0% since, to $15,285 in 2025. Among urology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$157,680in general payments, 2019–2025

Across 413 payments — averaging $381.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ferring Pharmaceuticals Inc.$30K
  • Astellas Pharma US Inc$27K
  • Sumitomo Pharma America, Inc.$26K
  • Lumenis, Inc$22K
  • Antares Pharma, Inc.$21K
  • Boston Scientific$15K
  • plus $15K from 33 others

What the payments were for

  • Consulting fees$5,6954%
  • Speaking & faculty fees$123,22678%
  • Travel & lodging$16,90911%
  • Food & beverage$10,9767%
  • Education$8751%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$157,680 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$42,454
Medicare patients
31
Services billed
409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron72$88,027
OrgovyxRelugolix21$56,870
MyrbetriqMirabegron38$26,786
Potassium Citrate ErPotassium Citrate29$2,591
Solifenacin Succinate23$1,301
Finasteride135$1,069
Tamsulosin Hcl153$1,034
Estradiol19$974
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim202$670
NitrofurantoinNitrofurantoin Macrocrystal26$402
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst18$163
Cephalexin12$93
Levofloxacin50$88
Oxybutynin Chloride ErOxybutynin Chloride11$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$25,984$144,89893 claims
Astellas Pharma US IncMyrbetriq$27,224$26,78638 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 urology providers in Texas.

Other urology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →